The initial, 12-month results have just been announced for two successful major trials. These two year, large, randomised phase III (registration) trials are for a new anti-VEGF drug called brolucizumab (RTH258) for the treatment of wet age-related macular degeneration (AMD).
The two trials involved more than 1,800 patients with wet AMD from 400 centres around the world, including some in Australia.
The studies showed that after 3 initial eye injections given a month apart, between 52 and 57% of people could be maintained on injections given every 12 weeks. The remainder of the participants were managed on injections every 8 weeks.
Brolucizumab is not yet available in Australia. Once it can be submitted for approval by its developer, Novartis, it will likely take a few years to move through the registration and reimbursement process.
30 June 2017